Academic Article
RDF
pages:
-
A phase II trial of dovitinib in BCG-unresponsive urothelial carcinoma with FGFR3 mutations or overexpression: Hoosier Cancer Research Network trial HCRN 12-157
-
A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: A Gynecologic Oncology Group study
-
A phase II trial of murine monoclonal antibody 17-1A and interferon-γ: Clinical and immunological data
-
A phase II trial of tamoxifen, premarin, methotrexate and 5-fluorouracil in metastatic breast cancer
-
A phase II trial of weekly topotecan for patients with secondary platinum-resistant recurrent epithelial ovarian carcinoma following the failure of second-line therapy
-
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus
-
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of VT-1161 oral tablets in the treatment of patients with distal and lateral subungual onychomycosis of the toenail*
-
A phase II, randomized, open label trial of preoperative letrozole versus letrozole (LET) in combination with bevacizumab (BEV) in post-menopausal women with newly diagnosed stage II/III breast cancer
-
A phase II/III randomized, multicenter trial of prednisone/sirolimus versus prednisone/ sirolimus/calcineurin inhibitor for the treatment of chronic graft-versus-host disease: BMT CTN 0801
-
A phase iia randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade RAD5 HIV-1 vaccine boost in healthy adults (HVTN204)
-
A Phase III equivalence trial of azithromycin versus benzathine penicillin for treatment of early syphilis
-
A phase III randomised controlled trial of single-dose triple therapy in COPD: The IMPACT protocol
-
A phase III randomized, doúble‐blind, multiinstitutional trial of vaccinia melanoma oncolysate‐active specific immunotherapy for patients with stage II melanoma
-
A phase III study evaluating the efficacy and safety of MBP8298 in secondary progressive MS.
-
A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734
-
A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: A Southeastern Cancer Study Group study
-
A phase III trial of high-dose cytosine arabinoside with or without etoposide in relapsed and refractory acute myelogenous leukemia. A Southeastern Cancer Study Group trial
-
A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma
-
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
-
A phase sensitive x-ray breast tomosynthesis system: Preliminary patient images with cancer lesions
-
A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis
-
A Phased Approach: The General Surgery Experience Adopting Entrustable Professional Activities in the United States
-
A phenomenological study of obesity and its impact on functional status, life-space mobility, and physical activity in southern African American older women
-
A phenomenological study of obesity and physical activity in southern African American older women
-
A phenomenological study of obesity and physical activity in Southern African American older women
-
A PheWAS study of a large observational epidemiological cohort of African Americans from the REGARDS study
-
A Philosophy for Smooth Contour Reconstruction.
-
A Philosophy of Successful Solutions: Creating a culture of performance
-
A phosholipid-apolipoprotein A-I nanoparticle containing amphotericin B as a drug delivery platform with cell membrane protective properties
-
A phosphatidylcholine-specific phospholipase C regulates activation of p42/44 mitogen-activated protein kinases in lipopolysaccharide-stimulated human alveolar macrophages
pages:
